425: Galera Therapeutics to Dissolve After Strategic Alternatives Fail, Announces Q2 2024 Results

Galera Therapeutics' board approves a plan to dissolve the company and liquidate assets after failing to find suitable strategic alternatives, with a stockholder vote scheduled for October 17, 2024.

Summary

• Galera Therapeutics announced its Board of Directors has approved a plan of liquidation and dissolution.
• The company will seek stockholder approval for the plan at a special meeting on or around October 17, 2024.
• If approved, the company intends to dissolve under Delaware law and distribute remaining cash to stockholders after settling debts.
• The Board may delay or abandon the dissolution if it's no longer in the company's best interest.
• The company's CFO and Chief Legal & Compliance Officer positions will be eliminated on August 31, 2024, reducing the workforce to three employees.
• Consulting agreements are expected with the departing officers to assist with wind-up activities.
• Second quarter 2024 financial results show research and development expenses at $1.4 million, down from $7.6 million in 2023.
• General and administrative expenses were $2.8 million, compared to $9.2 million in 2023.
• The net loss for the quarter was $(4.1) million, or $(0.07) per share, compared to $(20.7) million, or $(0.48) per share, in 2023.
• As of June 30, 2024, Galera had $10.7 million in cash and cash equivalents, expected to fund operations for at least the next twelve months.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the company's decision to dissolve and liquidate, indicating a failure to achieve its business objectives despite some cost-cutting measures and reduced losses in the recent quarter.

Positives

• The net loss decreased significantly in the second quarter of 2024 compared to the same period in 2023, from $(20.7) million to $(4.1) million.
• The company expects its existing cash and cash equivalents of $10.7 million will enable it to fund its operating expenses, including costs related to the Dissolution, for at least the next twelve months.

Negatives

• The company is dissolving and liquidating its assets, indicating a failure to achieve its business objectives.
• The positions of Chief Financial Officer and Chief Legal & Compliance Officer are being eliminated, reducing the workforce to three employees.
• The company ceased all clinical trial activity and suspended the clinical development of its product candidates as it explored potential strategic alternatives.

Risks

• The Board may decide to delay or not file the certificate of dissolution.
• The company's ability to sell or otherwise dispose of any of its remaining assets in Dissolution is uncertain.
• The company's ability to make liquidating distributions and the timing thereof is uncertain.
• The company faces risks related to receiving stockholder approval of Dissolution.

Future Outlook

Galera expects its existing cash and cash equivalents will enable it to fund its operating expenses, including costs related to the Dissolution, for at least the next twelve months. The company will continue to evaluate potential sale options for its pipeline assets while it continues to prepare for the planned Dissolution and, in the event that the Company is successful in a sale of any of its pipeline assets, the proceeds would be distributed to stockholders in accordance with the Plan of Dissolution.

Management Comments

• Following extensive consideration of potential strategic alternatives for the Company for close to a year and in order to maximize stockholder value, the Board of Directors has unanimously voted to approve and recommend for the stockholders to approve the Plan of Dissolution, said Mel Sorensen, M.D., Galeras President and CEO.
• On behalf of the management team, we extend our appreciation to all the patients, the clinical trial staff, our employees, the Board of Directors and our investors who have supported Galera throughout its journey.

Industry Context

The announcement reflects the challenges faced by clinical-stage biopharmaceutical companies in securing funding and achieving successful drug development outcomes, leading to strategic shifts like dissolution and asset liquidation.

Comparison to Industry Standards

• Given the company's focus on novel therapeutics for radiotherapy in cancer, comparable companies might include those developing similar treatments, such as Advantagene, Inc. which is developing gene-mediated cytotoxic therapy for cancer, or companies focused on supportive care for cancer patients undergoing radiotherapy, such as Helsinn Healthcare SA.
• However, the decision to dissolve and liquidate assets suggests that Galera was unable to secure additional funding or achieve clinical milestones comparable to successful peers in the oncology space.
• For example, Helsinn Healthcare SA has successfully commercialized supportive care products for cancer patients, demonstrating a viable business model in this area, which Galera was unable to replicate.

Management Changes

Stakeholder Impact

• Stockholders will receive any remaining cash after the wind down of operations and payment of creditors.
• Employees are impacted by workforce reductions, with the CFO and Chief Legal & Compliance Officer positions being eliminated.
• Patients and the medical community may be impacted by the cessation of clinical trials and the suspension of product development.

Next Steps

• The Company plans to hold a special meeting of stockholders on or around October 17, 2024 to seek approval of the dissolution of the Company and the Plan of Dissolution.
• The Company will file proxy materials relating to the Special Meeting with the Securities and Exchange Commission (the SEC).
• The Company will continue to evaluate potential sale options for its pipeline assets while it continues to prepare for the planned Dissolution.

Key Dates

Keywords

dissolution, liquidation, financial results, Galera Therapeutics, stockholder approval, strategic alternatives, avasopasem, rucosopasem